Is Sotolaxib (AMG510) included in medical insurance? How much does it cost?

Sotorasib (AMG510), commonly known as Sotorasib, is a revolutionary targeted therapy that is widely considered a major breakthrough in the treatment of lung cancer. Its mechanism of action targets the KRAS G12C mutation in tumor cells, a common cancer mutation. Sotorasiib blocks the abnormal proliferation and survival of tumor cells by specifically inhibiting the protein activity of KRAS G12C mutation.

Sotorasibu has not yet been approved for marketing in China. Therefore, if domestic patients want to use this drug, they must turn to overseas markets to purchase it. Overseas sotorasibu products include original drugs and generic drugs. The original drugs are mainly the European version and theHong Kong version, which are expensive, usually as high as tens of thousands of yuan.

However, in comparison, the prices of foreign generic drugs appear to be much more affordable. In particular, the price of generic drugs in Laos, such as Lucius and Daxiong brands, has dropped significantly recently, with prices only ranging from one thousand to two thousand yuan, which greatly alleviates the financial pressure on patients. It is worth mentioning that these generic drugs are highly consistent with the original drugs in terms of pharmaceutical ingredients.

Clinical trial results show that sotoraxib has shown significant efficacy in lung cancer patients, causing some tumors to shrink or stabilize, and even in some cases, the tumor burden is reduced or completely eliminated. In addition, sotoracib demonstrated durable efficacy and good tolerability, with a positive impact on patients' quality of life.

As a new type of targeted therapy drug, sotoracib has filled a long-term gap in the field of lung cancer treatment and provides an effective treatment option for lung cancer patients carryingKRAS G12C mutations. In addition, with in-depth research on its mechanism of action and clinical effects, the potential application of sotoraxib in other cancer types is also continuously explored.

To sum up, as a revolutionary drug for the treatment of lung cancer, sotoracib has significant efficacy and good safety, bringing new hope and opportunities to patients with lung cancer related toKRAS G12C mutation.